Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M14D1 in Advanced Solid Tumors
NCT06505824Phase 1Recruiting
- Sponsor
- Sichuan Biokin Pharmaceutical
- Start
- Aug 2024
- Primary completion
- Jun 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BL-M14D1 in small cell lung cancer (SCLC), Neuroendocrine Neoplasm (NEN) and solid tumor, sponsored by Sichuan Biokin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 21 days, Maximum Tolerated Dose at 21 days and 1 more. Started Aug 2024; status: recruiting.
02
Drugs
BL-M14D1
03
Conditions
small cell lung cancer (SCLC)Neuroendocrine Neoplasm (NEN)solid tumor
Beyond the preview
Go deeper on NCT06505824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06505824.